New therapeutic modalities: Transforming receptor pharmacology




Registration is now open!


Modulation of receptors and their intracellular signalling events continues to be a highly lucrative strategy for the discovery of novel therapeutics. However, the approaches used to modulate these targets have become much more varied in recent years. In this meeting we will discuss the new therapeutic modalities that are transforming our ability to pharmacologically modulate receptors and their intracellular signalling pathways.

Learning Outcomes: 
1. To better understand the mechanisms underlying cell signalling and receptor pharmacology
2. To translate that understanding into novel therapeutics
3. To understand the current state of the art in therapeutic modalities and the challenges that need to be addressed to move therapeutics into the clinic.

Read Dr Paul Miller's blog about why this meeting is unmissable!
 

Wednesday 2nd April
09:45 – 10:15 Registration and Refreshments
10:15 – 10:30 Welcome and Introduction
Session 1 Novel Pharmacological Tools for GPCRs - Graham Ladds (University of Cambridge)
10:30 – 11:00 Dr Andrew Buchanan, AstraZeneca Applications of AI/ML to identify novel GLP-1R agonists
11:00 – 11:30 Professor Dmitry Veprintsev, University of Nottingham  Quantifying signalling bias at beta2 adrenergic receptor using biophysical reporters of G protein recruitment.
11:30 – 11:45 OC1: Simone Mazzaferro Mechanism of GLP-1 receptor signaling in human POMC neurons
11:45 – 12:05 Catherine Wark, BMG Labtech - Partner Session Innovative microplate reader technology and optimisation for luminescence-based assay applications.
12:05 – 12:35 Dr Abigail Pearce,
Cambridge
Interdisciplinary approaches to understand GPCR signalling
12:35 – 13:05 Dr Andrew Jones, 
University of Cambridge
Talk title TBC
13:05 – 14:00 Lunch and Poster Viewing
Session 2 New Approaches to Manipulate Intracellular Signalling - Laura Itzhaki (University of Cambridge)
14:00 – 14:30 Dr James Hunt,
AstraZeneca
Biologics approaches to targeted protein degradation
14:30 – 15:00 Simon Cook, 
Babraham Research Institute 
Kinase inhibitors as Kinase degraders
15:00 – 15:15 OC2: Paul Fernyhough β-arrestin-biased agonism at the muscarinic acetylcholine type 1 receptor regulates neuronal phenotype via engaging casein kinase 2
15:15 – 15:30 OC3: Claudia Sisk Determining Signalling Bias of P2Y Receptors for Inflammatory and Haemostatic Behaviour of Platelets via HEK293T Cells
15:30 – 15:50 Pelago Biosciences - Partner Session CETSA-based evaluation of non-degraded PROTAC targets. Assessing degraders binding and MoA in live cells
15:50 – 16:20 Refreshment Break
16:20 – 16:50 Professor Miriam Stoeber, University of Geneva Signalling from internal membranes
16:50 – 17:05 OC4: Theo Redfern-Nichols Modelling Mutant Gαs proteins in Pseudohypoparathyroidism type 1c
17:05 – 17:20 OC5: Luke Heirene Data Driven Mathematical Modelling Highlights the Impact of Bivalency on the Optimum Affinity for Monoclonal Antibody Therapies
17:20 – 17:50 Hayley Sharpe,  Babraham Research Institute  Cell signalling by receptor tyrosine phosphatases
17:50 – 17:55 Closing Remarks

 

 
Thursday 3rd April
08:45 – 09:10 Registration and Refreshments
09:10 – 09:15 Welcome to day 2
Session 1 New modalities to modulate ion channels - Paul Miller (University of Cambridge)
09:15 – 09:45 Dr Sampurna Chakrabarti,
Max-Delbrück-Centrum für Molekulare Medizin (MDC) – Berlin
Phenotype-driven ultra-low input proteomics to identify novel targets for pain
09:45 – 10:15 Professor Stephanie Schorge, Department of Neuro, Physiology & Pharmacology, UCL Epilepsy Gene Therapy Using an Engineered Potassium Channel. Also established an ion channel database of mutations and disease effects for predicting therapies for new patients identified with ion channel mutations
10:15 – 10:30 OC6: Matthew Gold Do the transmembrane domains of adenylyl cyclases hold potential as targets for new therapeutic modalities?
10:30 – 10:45 OC7: Hyun Jee Han In Silico Enabled Discovery of  de novo protein binder, a preclinical NRP1 inhibitor, disrupts angiogenesis and tumour cell migration in gastric cancer
10:45 – 11:05 Partner Session
11:05 – 11:35   Refreshment Break & Posters 
11:35 – 11:50 OC8: Thomas Hill Development of a high-throughput hNav1.9 automated electrophysiology assay
11:50 – 12:20 Dr Vladimir Yarov-Yarovoy, Department of Physiology and Membrane Biology, University of California, Davis  Toward Design of Biologics Targeting Ion Channels

 
12:20 – 12:35 OC9: Jacob Browne A robust platform for recombinant production of animal venom toxin modulators of ion channels.
12:35 – 12:50 OC10: Sulin Liu Developing antibody modulators of GABAA receptors for in vivo applications
12:50 – 13:05 OC11: Caroline Wyatt  Ion Channel NanoBRET - The marriage of the large and the small to aid ion channel drug discovery
13:05 – 13:35 Professor Colleen Clancy, Department of Physiology and Membrane Biology, University of California Computational approaches to understand mechanisms of excitable disease in the heart and brain. Design detailed models of ion channel activity
13:35 – 13:45 Closing Remarks and Prizes
Conference Close



 

Dr Andrew Buchanan



Speaker: Dr Andrew Buchanan, AstraZeneca

Talk title: Applications of AI/ML to identify novel GLP-1R agonists

Biography: Dr Andrew Buchanan is a seasoned discovery & preclinical scientist, with 25 years of commercial R&D experience. He contributed to 20 antibody-based drugs entering first-time in human clinical studies of which to date three are marketed products. He has lead teams responsible for platform technologies and drug pipeline delivery to first in human studies. His current focus is on biologics targeting strategies, AI/ML innovation and early career mentoring. He was elected Fellow of the Royal Society of Chemistry in 2020 and with colleagues contributed over 40 original papers and patents. 

Professor Dmitry Veprintsev



Speaker: Dmitry Veprintsev, Professor of Molecular & Cellular Pharmacology, University of Nottingham & co-founder and CEO, Z7 Biotech Ltd, a precision pharmacology CRO.

Talk title: Quantifying signalling bias at beta2 adrenergic receptor using biophysical reporters of G protein recruitment.

Biography: Dmitry is Professor of Molecular and Cellular Pharmacology at the Centre of Membrane Proteins and Receptors (COMPARE), University of Nottingham, where he provides leadership in structural and biophysical pharmacology of G protein coupled receptors. Following a PhD in protein folding at the Russian Academy of Sciences and at the Ohio State University, USA, he joined the MRC Centre for Protein Engineering and later the MRC Laboratory of Molecular Biology in Cambridge, UK as a postdoctoral fellow and as a staff scientist, focusing on the biophysical studies of the tumour suppressor p53. In 2010 he became a group leader at the Paul Scherrer Institute and ETH Zürich in Switzerland where focused his research on G protein-coupled receptors (GPCRs). In 2017 Dmitry joined COMPARE, a joined venture between the University of Birmingham and the University of Nottingham. In 2021 he co-founded Z7 Biotech, a CRO developing and providing innovative GPCR drug screening and precision pharmacology services.  See www.veprintsevlab.org and www.z7bio.com for more information.

Dr Abigail Pearce 



Speaker: Dr Abigail Pearce, Cambridge

Talk title: Interdisciplinary approaches to understand GPCR signalling

Biography: Abigail Pearce completed her PhD at the University of Cambridge in 2022, before starting a postdoc under the supervision of Prof Graham Ladds. Her research is focused on the structural mechanisms underlying agonist bias at G Protein-Coupled Receptors, with particular interest in Gα-subtype bias of the adenosine receptor family.

Simon Cook



Speaker: Simon Cook, Babraham Research Institute

Talk title: Kinase inhibitors as Kinase degraders

Biography: After a Biochemistry degree at Royal Holloway College, University of London (1983-86) Simon undertook his PhD in Michael Wakelam’s laboratory at the University of Glasgow (1987-91), studying signalling by Phospholipase-C and -D. He then moved to Post-Doc with Frank McCormick at ONYX Pharmaceuticals in the San Francisco Bay Area where he studied the then emerging RAS-RAF-MEK-ERK1/2 pathway (1991-94). Simon stayed on at ONYX as a Associate Staff Scientist, Staff Scientist and member of the RAS Group Steering Committee (1994-1997). He also served as Project Manager for the Inflammation Project which he guided to corporate partnership with ParkeDavis/Warner-Lambert securing $10M funding for 3yrs to progress drug-discovery projects.

Simon joined the Babraham Institute as a Tenure-Track Group Leader in 1997 and held a Cancer Research UK Senior Cancer Research Fellowship from 2000-2006. From 2013-2021 he coordinated Knowledge Exchange and Commercialisation activities within the Institute. Since September 2020, Simon has led the Institute’s Signalling Programme and is currently Institute Director.

Throughout his career Simon has collaborated extensively with the Biotech and Pharma sector. Collaborations with AstraZeneca for more than 15 years identified mechanisms of innate and acquired resistance to protein kinase inhibitors including MEKi, FGFRi and mTORi. He has also collaborated with Astex Pharmaceuticals, MISSION Therapeutics and PhoreMost (through a collaborative Innovate UK award) to translate his knowledge of signalling pathways.

Professor Miriam Stoeber



Speaker: Professor Miriam Stoeber, University of Geneva

Talk title: Signalling from internal membranes

Biography: Miriam Stoeber is an Associate Professor at the Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland. She established her independent research group in 2019, with the support of a Starting Grant of the Swiss National Science Foundation. Her team investigates the (sub)cellular logic of GPCR signaling and develops new nanobody-based GPCR modulators.

Prof. Stoeber obtained her PhD at ETH Zurich in 2012, performed a short-term postdoc at the University of Oxford in 2013, and did a 5-year postdoc at the University of California San Francisco (UCSF) from 2014-2019. She is an EMBO Young Investigator since 2024 and a recipient of the FEBS Excellence Award 2023.

Hayley Sharpe 



Speaker: Hayley Sharpe, Babraham Institute, Cambridge

Biography: Hayley Sharpe is a Group Leader in the Signalling programme at the Babraham Institute, Cambridge. She established her group at the Cambridge institute for medical research in 2016 with the support of a Wellcome/Royal Society Henry Dale fellowship, before moving to the Babraham Institute in 2019. She is a Lister Institute prize fellow and EMBO young investigator since 2020 and recipient of an ERC consolidator grant in 2023. 
Her lab focuses on the interplay between protein tyrosine phosphatase and redox signalling in different areas including immunology, cancer and ageing. 

Talk title: Cell signalling by receptor tyrosine phosphatases

Abstract: Protein tyrosine phosphorylation is a critical, reversible post translational modification for numerous cellular processes, and is often dysregulated in diseases such as cancer. The actions of kinases and phosphatases control cellular phosphotyrosine levels. The cysteine-based protein tyrosine phosphatases (PTPs) can be modified by reversible oxidation. We have used systematic approaches to identify receptor substrates to understand their function in cell decision making. Although there are no clinical inhibitors of PTPs to date, there are concerted efforts to inhibit their functions for therapeutic gain, and there is the potential to synthetically target them to dephosphorylate pathological proteins in so called PhosTAC approaches. By understanding PTP mechanisms we hope to reveal additional therapeutic modalities.

Dr Sampurna Chakrabarti



Speaker: Dr Sampurna Chakrabarti, Max-Delbrück-Centrum für Molekulare Medizin (MDC) - Berlin

Talk title: Phenotype-driven ultra-low input proteomics to identify novel targets for pain

Biography: Sampurna Chakrabarti, PhD (she/her) was an Alexander von Humboldt fellow and now a senior postdoctoral scientist at the Max Delbrück Center for Molecular Medicine in Berlin working on mechanosensation and pain. Dr Chakrabarti focuses on understanding the different subsets of pain sensing neurons by mapping their function to molecular signature using a variety of tools including electrophysiology and neuroproteomics. Dr Chakrabarti has co-authored more than 10 research papers in leading journals including Science, PAIN and Arthritis and Rheumatology and serves as reviewer in journals such as, Science Advances, European Journal of Pain, Pain Reports.

Dr Vladimir Yarov-Yarovoy

Speaker: Dr Vladimir Yarov-Yarovoy, Department of Physiology and Membrane Biology, University of California, Davis

Talk title: Peptide and small molecule design against voltage gated ion channels

Biography: Dr. Vladimir Yarov-Yarovoy earned an M.S. Degree in Physics at the Moscow State University in Moscow, Russia (mentored by Dr. Galina Mironova), and then Ph.D. Degree in Biochemistry and Molecular Biology at the Oregon Health Science University in Portland, Oregon (mentored by Dr. Keith Garlid). Dr. Yarov-Yarovoy was a postdoctoral fellow in Biophysics (mentored by William Catterall) and Computational Biology (mentored by David Baker) and then a Research Assistant Professor in the Department of Pharmacology at the University of Washington in Seattle, Washington. He joined UC Davis as an Assistant Professor in Physiology and Membrane Biology in 2011 and became a full Professor in 2020. Dr. Vladimir Yarov-Yarovoy’s research interests and expertise encompass neuroscience, protein structure, and computational biology. The main focus of his research group is on computational design of subtype-specific ion channel modulators, structure and function studies of voltage-gated ion channels, and development of computational methods for membrane protein structure prediction and design. Recent advances in computational protein design, determination of high-resolution ion channel structures and discoveries of natural peptides that target them with high affinity, set a stage for computational design of novel ion channel modulators.

UC Davis Health profile:
https://health.ucdavis.edu/physiology/faculty/yarovoy.html

LinkedIn profile:
https://www.linkedin.com/in/vladyy/

Abstract: Ion channels are pivotal in regulating electrical activity in excitable cells and are critical pharmaceutical targets for treating many diseases, including cardiac arrhythmia and neuropathic pain. Despite their significance, challenges such as achieving target selectivity persist in VGIC drug development. Recent progress in deep learning methods has enabled structure-guided computational design of biologics targeting ion channels. These developments coincide with a surge in experimental structural data for VGICs, providing a rich foundation for computational design efforts. Our interdisciplinary research team has recently developed a novel structure-based approach employing deep-learning-based RoseTTAFold, ProteinMPNN, and AlphaFold computational methods to design biologics targeting different regions of ion channels, including the pore domain, voltage-sensing domains, and interface with auxiliary subunits. We generated preliminary proof-of-concept data showing that we can successfully design small proteins targeting extracellular region of the selectivity filter of an ion channel. Our novel approach of designing biologics targeting ion channels could be widely applicable for generating molecular tools to study ion channel activity and to develop novel therapeutics targeting specific ion channel subtypes in a state-dependent manner.


Professor Colleen Clancy 



Speaker: Professor Colleen Clancy, Department of Physiology and Membrane Biology, University of California, Davis

Talk title: Computational approaches to understand mechanisms of excitable disease in the heart and brain. Design detailed models of ion channel activity

Biography: Dr. Clancy is the Airline Miller Rolkin Professor in Health Innovation and serves as the Director of Precision Medicine and Data Sciences at UC Davis. She is the inaugural Editor-in-Chief of the Journal of Precision Medicine. Clancy’s research focuses on developing and implementing computational modeling and simulation of excitable systems that may serve to mechanistically link genotype with phenotype. Dr. Clancy's research focuses on understanding how abnormal genes, proteins, cells, and tissues disrupt complex systems to cause disease. 

Dr. Clancy earned her PhD in Biophysics & Physiology from Case Western Reserve University and completed her Postdoctoral Training at Columbia University. She has published over 100 works, and actively serves in editorial and advisory capacities for several journals and organizations. Her research, supported by multiple NIH programs. In addition to her research program, Dr. Clancy has made significant contributions to the UC Davis School of Medicine, where she has played pivotal roles in academic personnel actions, including recruitment, appointment, merit reviews, faculty development, and more. She has chaired the UC System-wide Committee on Affirmative Action and Diversity and has been involved in various committees and task forces at UC Davis. Recognized for her leadership, Clancy is an alumna of the National Executive Leadership in Academic Medicine (ELAM) program and has received numerous awards, including the 2014 Dean's Excellence in Mentoring Award, the 2018 Deans’ Team Award for Excellence in Research, the 2018–19 Chancellor’s Achievement Award for Diversity and Community and the 2020 UC Davis School of Medicine Research Award.

Tickets


ECR Non-Member Ticket Non-Member Ticket £150.00
Full, Fellow and Honorary Fellow Member Ticket Member Ticket £185.00
Standard Non-Member Ticket Non-Member Ticket £350.00
Undergraduate, ECR, Retired Full and Retired Fellow Member Ticket Member Ticket £85.00

Abstract submissions are now closed. 
 

Abstract submitters will be notified from 10 March on the outcome of your submission, please contact us on meetings@bps.ac.uk should you have any questions.




 

Sponsorship Opportunities

Unlock a range of exciting sponsorship opportunities designed to benefit your organisation! We offer flexible packages to suit different needs and budgets, and we’d be happy to create a tailored solution just for you.

Download the Prospectus Now

If you have any questions or wish to connect with Abdul our Sponsorship and Partnerships Manager on abdul.hayee@bps.ac.uk



 

At Pelago Bioscience, we’re here to help you make faster, better-informed decisions in drug discovery. In 2010, our founders began to develop our proprietary CETSA® (Cellular Thermal Shift Assay) technology, publishing a seminal research paper in Science 2013. Since then, Pelago has become the leading CRO providing actionable, biologically relevant insights at the pre-clinical stage. Unlike traditional methods, CETSA allows us to assess drug-target interactions in physiologically relevant, unmodified cellular environments—so you can be confident that what you see in cells, you will also see in patients.  
 
Our services rest on four pillars:  

•            Certainty in Biological Relevance: CETSA’s physiological approach helps minimize late-stage risks.  
•            Fast & Early Confidence: We deliver actionable insights in just 4-10 weeks, eliminating unnecessary complexities so you can make decisions faster.  
•            Insights & Progress: Our data supports compound prioritization and predicts future research steps, reducing project costs.  
•            Extended Team Support: We work as your dedicated partner, designing fit-for-purpose studies that align with your goals.  
 
With Pelago, you gain more than just data; you gain a trusted partner in your discovery journey 



BMG LABTECH is a leading developer and manufacturer of microplate reader instrumentation, used in pharmaceutical and biotech industries, as well as in academic research.

With more than 35 years’ specialised experience, we actively develop innovative optical detection solutions to deliver the best performance for all microplate reader assays. BMG LABTECH instruments are built for longevity by design, and are supported by applications and service support to ensure our customers can advance their research with confidence.


Society Membership 


We are a global community at the heart of pharmacology. Founded in 1931 – with just 38 members – we now represent around 4,000 members from over 60 countries.

As a vibrant science that studies drug action, pharmacology lies at the heart of biomedical science, linking together chemistry, physiology and pathology. Pharmacologists work closely with a wide variety of other disciplines that make up modern biomedical science, including but not limited to biochemistry, neuroscience, molecular and cell biology, genetics, immunology and cancer biology.

Read about how membership of professional Societies can enhance career development.

For more details on our membership categories, fee and benefits, please visit the Society Membership page. This information is also available to download now.

If you’d like to speak with the membership team, feel free to reach out to membership@bps.ac.uk for further assistance.

From
02 April 2025
To
03 April 2025
Venue
St John's College, St John's Street, Cambridge, CB2 1TP




Connect with us:

© British Pharmacological Society, The Schild Plot, 16 Angel Gate, City Road, London EC1V 2PT, United Kingdom

loading